GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) Stock Price

GSKStock

$49.51+14.02%52W

Market Cap$99.19B

P/E13.10x

PEG Ratio5.84

Div yield3.92%

Beta1.21

GSK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-22.51%

Price vs S&P 500 (4W)-1.21%

PEG Ratio5.84

VGM Score59.31

P/E Ratio (Annual)13.10x

Indicated Dividend Yield (Annual)3.92%

P/CF (Annual)9.67x

Book Value / Share (Quarterly)$5.77

P/TBV (Annual)325.88x

Indicated Dividend (Annual)$90.56

Revenue Growth (3Y)3.66%

Cash Flow / Share (Quarterly)$1.74

Payout Ratio (TTM)55.30%

Price vs S&P 500 (YTD)-8.88%

Gross Margin (TTM)73.56%

Net Profit Margin (TTM)14.52%

EPS (TTM)$1.57

10-Day Avg Trading Volume5.06M

EPS Excl Extra (TTM)$1.57

Revenue Growth (5Y)6.05%

EPS (Annual)$1.85

Dividend / Share (Annual)$0.83

ROI (Annual)16.76%

Gross Margin (Annual)73.05%

Net Profit Margin (5Y Avg)22.14%

Cash / Share (Quarterly)$1.01

P/E Basic Excl Extra (TTM)15.53x

Revenue Growth QoQ (YoY)5.30%

EPS Growth (5Y)-0.54%

P/E Normalized (Annual)13.10x

ROA (Last FY)9.35%

Revenue Growth TTM (YoY)4.97%

EBITD / Share (TTM)$2.14

ROE (5Y Avg)52.18%

Operating Margin (TTM)19.48%

Cash Flow / Share (Annual)$1.55

P/B Ratio4.24x

P/B Ratio (Quarterly)4.54x

Net Income / Employee (Annual)$113,872

EV / Revenue (TTM)2.71x

Net Interest Coverage (TTM)11.98x

ROA (TTM)7.81%

EPS Growth QoQ (YoY)-69.50%

EV / EBITDA (TTM)13.72x

EPS Incl Extra (Annual)$1.85

Current Ratio (Annual)0.82x

Quick Ratio (Quarterly)0.52x

3-Month Avg Trading Volume4.99M

52-Week Price Return14.02%

EV / Free Cash Flow (Annual)18.92x

P/E Incl Extra (TTM)15.53x

Revenue / Employee (TTM)$661,521

Tangible BV / Share (Quarterly)$0.28

P/S Ratio (Annual)2.29x

Asset Turnover (Annual)0.53x

52-Week High$3039.24

Operating Margin (5Y Avg)19.76%

EPS Excl Extra (Annual)$1.85

CapEx CAGR (5Y)5.92%

Tangible BV CAGR (5Y)-48.07%

26-Week Price Return-12.60%

Quick Ratio (Annual)0.52x

13-Week Price Return-2.82%

Total Debt / Equity (Annual)1.08x

Current Ratio (Quarterly)0.82x

Enterprise Value$119.87B

Revenue / Share Growth (5Y)5.60%

Asset Turnover (TTM)0.54x

Book Value / Share Growth (5Y)2.08%

Revenue / Employee (Annual)$650,867

Inventory Turnover (Annual)1.52x

Pretax Margin (Annual)22.66%

Cash / Share (Annual)$1.03

3-Month Return Std Dev25.26%

Gross Margin (5Y Avg)71.26%

Net Income / Employee (TTM)$96,025

EBITDA CAGR (5Y)5.78%

EBITDA Interim CAGR (5Y)-16.70%

ROE (Last FY)34.90%

Net Interest Coverage (Annual)6.49x

EPS Basic Excl Extra (Annual)$1.85

P/FCF (TTM)14.04x

Receivables Turnover (TTM)4.42x

EV / Free Cash Flow (TTM)16.88x

Total Debt / Equity (Quarterly)1.03x

EPS Incl Extra (TTM)$1.57

Receivables Turnover (Annual)5.68x

ROI (TTM)13.70%

Dividend Growth Rate (5Y)-8.93%

P/S Ratio (TTM)2.25x

Pretax Margin (5Y Avg)17.50%

Revenue / Share (Annual)$10.57

Tangible BV / Share (Annual)$0.06

Forward P/E10.07x

Free OCF CAGR (5Y)-5.17%

Price vs S&P 500 (52W)-1.51%

P/E Ratio (TTM)15.53x

EPS Growth TTM (YoY)42.32%

Year-to-Date Return2.08%

5-Day Price Return5.17%

EPS Normalized (Annual)$1.85

ROA (5Y Avg)10.49%

Net Profit Margin (Annual)17.50%

Month-to-Date Return1.66%

Cash Flow / Share (TTM)$2.67

EBITD / Share (Annual)$2.59

EPS Growth (3Y)-27.62%

Operating Margin (Annual)24.28%

LT Debt / Equity (Annual)0.86x

P/CF (TTM)8.99x

ROI (5Y Avg)19.88%

P/E Excl Extra (TTM)15.53x

LT Debt / Equity (Quarterly)0.79x

EPS Basic Excl Extra (TTM)$1.57

P/TBV (Quarterly)95.06x

Payout Ratio (Annual)44.86%

P/B Ratio (Annual)4.51x

Dividend / Share (TTM)$0.86

Inventory Turnover (TTM)1.42x

Pretax Margin (TTM)17.78%

Book Value / Share (Annual)$5.35

Price vs S&P 500 (13W)-5.50%

Net Margin Growth (5Y)-5.81%

Dividend Yield (TTM)3.56%

Beta1.21x

P/FCF (Annual)15.74x

Revenue / Share (TTM)$10.89

ROE (TTM)28.35%

52-Week Low$2120.28

vGradeC

gGradeC

mGradeB

vgmGradeC

GSK Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 28, 2026	$1.67	$1.79	+7.24%(+$0.12)
Q1 2026	Apr 29, 2026	$1.55	$1.67	+7.88%(+$0.12)
Q4 2025	Feb 4, 2026	$0.83	$0.93	+11.93%(+$0.09)
Q3 2025	Oct 29, 2025	$1.68	$1.94	+15.37%(+$0.25)
Q2 2025	Jul 30, 2025	$1.48	$1.65	+11.73%(+$0.17)

GSK Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.50

3.47

3.53

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About GSK plc American Depositary Shares (Each representing two Ordinary Shares)

A leading global pharmaceutical company with a diversified therapeutic portfolio spanning respiratory, vaccines, antivirals, and specialty care. The company is expanding its presence in high-growth areas including oncology and immunology. Strategic partnerships and joint ventures, particularly in HIV treatment, strengthen its market position across key segments.

GSK Next Earnings Report

Report dateOct 28, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$1.77

Revenue estimate$11.73B

Also reporting on Oct 28, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for October 2026

GSK Insider Transactions

SellAug 21, 2026
Martinez-Davis (Maya)
Shares: 44,397Value: $2.32M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

AMGNAmgen IncBiological Products
LINLinde plc Ordinary ShareIndustrial Chemicals
GILDGilead Sciences IncBiological Products
ULUnilever plcSoap & Detergents
MRNAModerna, Inc. Common StockBiological Products
ECLEcolab, Inc.Soap & Detergents
CLColgate-Palmolive CompanyCosmetics & Toiletries
APDAir Products & Chemicals, Inc.Industrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.5

Buy

Consensus rating

Price Range (33 wk)

Low$46.27

High$59.18